📣 VC round data is live. Check it out!
- Public Comps
- Siemens Healthineers
Siemens Healthineers Valuation Multiples
Discover revenue and EBITDA valuation multiples for Siemens Healthineers and similar public comparables like Edwards Lifesciences, IDEXX Laboratories, Waters, Agilent and more.
Siemens Healthineers Overview
About Siemens Healthineers
Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (56% of sales in fiscal 2025) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (18% of sales) offers radiotherapy and other oncology solutions. The diagnostics segment (19%) includes in vitro diagnostics and point-of-care diagnostics. The advanced therapies (now part of precision therapy) segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. The Americas represents 44% of total sales, Europe, Middle East, and Africa 32%, and Asia-Pacific, including China (11%), the remainder.
Founded
2017
HQ

Employees
73.8K
Website
Financials (LTM)
EV
$42B
Valuation Multiples
Start free trialSiemens Healthineers Financials
Siemens Healthineers reported last 12-month revenue of $27B and EBITDA of $5B.
In the same LTM period, Siemens Healthineers generated $11B in gross profit, $5B in EBITDA, and $3B in net income.
Revenue (LTM)
Siemens Healthineers P&L
In the most recent fiscal year, Siemens Healthineers reported revenue of $27B and EBITDA of $5B.
Siemens Healthineers is profitable as of last fiscal year, with gross margin of 39%, EBITDA margin of 20%, and net margin of 9%.
Financial data powered by Morningstar, Inc.
Siemens Healthineers Stock Performance
Siemens Healthineers has current market cap of $44B, and enterprise value of $42B.
Market Cap Evolution
Siemens Healthineers' stock price is $39.75.
Siemens Healthineers share price decreased by 2.5% in the last 30 days, and by 26.0% in the last year.
Siemens Healthineers has an EPS (earnings per share) of $2.24.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $42B | $44B | -0.1% | -2.5% | -20.1% | -26.0% | $2.24 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSiemens Healthineers Valuation Multiples
Siemens Healthineers trades at 1.5x EV/Revenue multiple, and 7.8x EV/EBITDA.
EV / Revenue (LTM)
Siemens Healthineers Financial Valuation Multiples
As of May 15, 2026, Siemens Healthineers has market cap of $44B and EV of $42B.
Siemens Healthineers has a P/E ratio of 17.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Siemens Healthineers Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Siemens Healthineers Margins & Growth Rates
Siemens Healthineers grew revenue by 1% and EBITDA by 0% in the last fiscal year.
In the most recent fiscal year, Siemens Healthineers reported gross margin of 39%, EBITDA margin of 20%, and net margin of 9%.
Siemens Healthineers Margins
Siemens Healthineers Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Siemens Healthineers Operational KPIs
Siemens Healthineers' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Siemens Healthineers' Rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Siemens Healthineers' Rule of X is 26% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Siemens Healthineers Competitors
Siemens Healthineers competitors include Edwards Lifesciences, IDEXX Laboratories, Waters, Agilent, Alcon, ResMed, Mindray, GE HealthCare, Philips and Boston Scientific.
Most Siemens Healthineers public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 7.2x | 6.9x | 24.2x | 22.8x | |||
| 10.0x | 9.6x | 28.5x | 27.3x | |||
| 11.9x | 8.6x | 33.4x | 25.4x | |||
| 4.8x | 4.7x | 16.8x | 16.1x | |||
| 3.3x | 3.3x | 12.8x | 12.7x | |||
| 5.6x | 5.1x | 14.9x | 13.2x | |||
| 5.3x | 5.3x | 15.6x | 16.0x | |||
| 1.8x | 1.7x | 9.7x | 9.9x | |||
This data is available for Pro users. Sign up to see all Siemens Healthineers competitors and their valuation data. Start Free Trial | ||||||
Siemens Healthineers M&A Activity
Siemens Healthineers has acquired 8 companies to date.
Last acquisition by Siemens Healthineers was on August 26th 2024. Siemens Healthineers acquired Advanced Accelerator Applications for $224M (EV/Revenue multiple of ).
Latest Acquisitions by Siemens Healthineers
| Description | Advanced Accelerator Applications is a Paris-headquartered radiopharmaceutical company developing targeted radioligand therapies and diagnostics for oncology and rare diseases. Acquired by Novartis in 2018, it commercializes Lutathera for neuroendocrine tumors and Pluvicto for prostate cancer, with production at seven global cyclotrons. The firm advances pipeline agents like 177Lu-DOTATATE and 68Ga-DOTATOC, supported by FDA approvals in 2018 and 2022. Operating in over 30 countries with 1,200 employees, it focuses on theranostics platforms for precision medicine in Europe and North America. | Varian is a Palo Alto-headquartered provider of radiotherapy equipment and oncology software. The company manufactures linear accelerators, proton therapy systems, and brachytherapy devices used in over 7,000 cancer centers globally. Its TrueBeam platform delivers image-guided radiation with sub-millimeter precision. Acquired by Siemens Healthineers in 2021, Varian also supplies X-ray tubes for security screening at borders and ports. | Corindus is a Waltham, Massachusetts-based developer of robotic systems for interventional cardiology. The company's CorPath GRX platform enables precise percutaneous coronary interventions from radiation-shielded consoles. Founded in 2002, Corindus supports remote procedures in cath labs worldwide. | Fast Track Diagnostics is a Luxembourg-headquartered supplier of multiplex PCR diagnostic kits for infectious diseases. The company manufactures assays that simultaneously detect viruses, bacteria, fungi, and parasites from clinical samples like respiratory swabs or cerebrospinal fluid. Validated for use in over 60 countries, its panels cover panels for meningitis, gastroenteritis, and pneumonia pathogens. Fast Track Diagnostics serves hospitals, labs, and public health systems worldwide, with products CE-marked and distributed through partners in Europe, Asia, and the Americas. | |
| HQ Country | |||||
| HQ City | Lyon | San Francisco, CA | Boston, MA | Sliema | |
| Deal Date | 26 Aug 2024 | 2 Aug 2020 | 8 Aug 2019 | 15 Dec 2017 | |
| Valuation | $224M | $16B | $1B | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Siemens Healthineers acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Siemens Healthineers Investment Activity
Siemens Healthineers has invested in 3 companies to date.
Latest investment by Siemens Healthineers was on April 16th 2026. Siemens Healthineers invested in ScreenPoint Medical in their $14M Undisclosed stage round (EV/Revenue multiple of ).
Latest Investments by Siemens Healthineers
| Description | ScreenPoint Medical is a Nijmegen-headquartered medical technology company specializing in AI-driven image analysis for mammography and digital breast tomosynthesis. Its Transpara software assists radiologists in detecting breast cancer, earning FDA clearance in 2020 and CE marking for European markets. Deployed in clinics across the United States and Europe, it processes large curated image databases to improve screening accuracy and workflow efficiency. | VedaBio is a San Diego-headquartered molecular diagnostics company developing the Ranger platform for amplification-free detection of nucleic acids. Launched in 2022, it uses silicon photonic chips and CRISPR enzymes to identify multiple pathogens including SARS-CoV-2, influenza, and RSV in under 5 minutes from clinical samples. VedaBio's technology achieves single-molecule sensitivity without PCR, validated in CLIA labs for point-of-care testing. The company raised Series A funding in 2023 and partners with Roche Diagnostics for commercialization. | ScreenPoint Medical is a Nijmegen-headquartered medical technology company specializing in AI-driven image analysis for mammography and digital breast tomosynthesis. Its Transpara software assists radiologists in detecting breast cancer, earning FDA clearance in 2020 and CE marking for European markets. Deployed in clinics across the United States and Europe, it processes large curated image databases to improve screening accuracy and workflow efficiency. | Babson Diagnostics is a Cary-headquartered healthcare technology company advancing point-of-care blood testing in the United States. Its BetterWay platform uses finger-prick collection requiring one-tenth the volume of standard venipuncture, delivering lab-comparable results from retail pharmacies like CVS in under eight hours. The system analyzes biomarkers for wellness, chronic disease, and medication monitoring, partnering with laboratory networks for processing. | |
| HQ Country | |||||
| HQ City | Nijmegen | San Diego, CA | Nijmegen | Austin, TX | |
| Deal Date | 16 Apr 2026 | 23 Sep 2025 | 27 Jul 2021 | 29 Jun 2021 | |
| Round | Undisclosed stage | Series A | Series C | Series B | |
| Raised | $14M | $25M | $28M | $31M | |
| Investors | Jerry Murdock; Siemens Healthineers | Siemens Healthineers | Insight Partners; OostNL; Siemens Healthineers | Emerald Development Managers; Infinitum Partners; Lago Consulting & Services; Prism Venture Management; Siemens Healthineers | |
| Valuation | undisclosed | undisclosed | undisclosed | $196M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Siemens Healthineers investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Siemens Healthineers
| When was Siemens Healthineers founded? | Siemens Healthineers was founded in 2017. |
| Where is Siemens Healthineers headquartered? | Siemens Healthineers is headquartered in Germany. |
| How many employees does Siemens Healthineers have? | As of today, Siemens Healthineers has over 73K employees. |
| Is Siemens Healthineers publicly listed? | Yes, Siemens Healthineers is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of Siemens Healthineers? | Siemens Healthineers trades under SHL ticker. |
| When did Siemens Healthineers go public? | Siemens Healthineers went public in 2018. |
| Who are competitors of Siemens Healthineers? | Siemens Healthineers main competitors include Edwards Lifesciences, IDEXX Laboratories, Waters, Agilent, Alcon, ResMed, Mindray, GE HealthCare, Philips, Boston Scientific. |
| What is the current market cap of Siemens Healthineers? | Siemens Healthineers' current market cap is $44B. |
| What is the current revenue of Siemens Healthineers? | Siemens Healthineers' last 12 months revenue is $27B. |
| What is the current revenue growth of Siemens Healthineers? | Siemens Healthineers revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Siemens Healthineers? | Current revenue multiple of Siemens Healthineers is 1.5x. |
| Is Siemens Healthineers profitable? | Yes, Siemens Healthineers is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Siemens Healthineers? | Siemens Healthineers' last 12 months EBITDA is $5B. |
| What is Siemens Healthineers' EBITDA margin? | Siemens Healthineers' last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Siemens Healthineers? | Current EBITDA multiple of Siemens Healthineers is 7.8x. |
| What is the current FCF of Siemens Healthineers? | Siemens Healthineers' last 12 months FCF is $3B. |
| What is Siemens Healthineers' FCF margin? | Siemens Healthineers' last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Siemens Healthineers? | Current FCF multiple of Siemens Healthineers is 14.5x. |
| How many companies Siemens Healthineers has acquired to date? | As of May 2026, Siemens Healthineers has acquired 8 companies. |
| What was the largest acquisition by Siemens Healthineers? | $16B acquisition of Varian on 2nd August 2020 was the largest M&A Siemens Healthineers has done to date. |
| What companies Siemens Healthineers acquired? | Siemens Healthineers acquired Varian, Corindus, Advanced Accelerator Applications, Epocal, Fast Track Diagnostics, Medicalis, Conworx Technology, and NEO New Oncology AG. |
| In how many companies Siemens Healthineers has invested to date? | As of May 2026, Siemens Healthineers has invested in 3 companies. |
| What was the last Siemens Healthineers investment? | On 16th April 2026 Siemens Healthineers invested in ScreenPoint Medical, participating in a $14M Undisclosed stage round, alongside Jerry Murdock. |
| In what companies Siemens Healthineers invested in? | Siemens Healthineers invested in Babson Diagnostics, ScreenPoint Medical, and VedaBio. |
See public comps similar to Siemens Healthineers
Lists including Siemens Healthineers
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.



